B. Riley Initiates Coverage on DexCom to Neutral

B. Riley Initiates Coverage on DexCom(NASDAQ:DXCM). The shares have been rated Neutral. The rating by B. Riley was issued on Sep 27, 2016.

In a different note, On Sep 16, 2016, Desjardins said it Upgrades its rating on DexCom. The shares have been rated ‘Buy’ by the firm. On Sep 14, 2016, BTIG Research said it Downgrades its rating on DexCom. The shares have been rated ‘Neutral’ by the firm. On Jul 15, 2016, Deutsche Bank said it Maintains its rating on DexCom. In the research note, the firm Raises the price-target to $90.00 per share. The shares have been rated ‘Buy’ by the firm.

DexCom (DXCM) shares turned negative on Fridays trading session with the shares closing down -0.14 points or -0.16% at a volume of 10,25,933. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $89.02. The peak price level was also seen at $89.02 while the days lowest was $86.81. Finally the shares closed at $87.66. The 52-week high of the shares is $96.38 while the 52-week low is $47.92. According to the latest information available, the market cap of the company is $7,353 M.

DexCom(DXCM) last announced its earnings results on Aug 2, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $137.30M. Analysts had an estimated revenue of $132.59M. Earnings per share were $-0.24. Analysts had estimated an EPS of $-0.12.

Several Insider Transactions has been reported to the SEC. On Sep 23, 2016, Jess Roper (SVP, CFO) sold 2,470 shares at $93.99 per share price.Also, On Sep 22, 2016, Andrew K Balo (EVP, Clinical and Regulatory) sold 5,000 shares at $92.87 per share price.On Sep 16, 2016, Kevin R Sayer (President & CEO) sold 7,000 shares at $91.79 per share price, according to the Form-4 filing with the securities and exchange commission.

Dexcom Inc. (Dexcom) is a medical device company. The Company is focused on the design development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products consist of DexCom G4 DexCom G4 PLATINUM and DexCom Share System. The DexCom G4 PLATINUM with Share uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone to transmit glucose information to applications on the mobile devices of up to five designated recipients or followers who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have an Internet connection. SweetSpot’s data transfer service is a Medical Device Data System (MDDS) and allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

DexCom - Is it time to Sell?

Top Brokerage Firms are advising their investors on DexCom. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.